Pentwater Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Pentwater Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14,000	Closed	-$614K	–	184
2022 Q1	$614K	Sell	14,000 -25,500	-65%	-$1.19M	0.01%	144
2021 Q4	$2.4M	Buy	39,500 +27,500	+229%	+$1.52M	0.03%	123
2021 Q3	$499K	Hold	12,000	–	–	0.01%	210
2021 Q2	$364K	Hold	12,000	–	–	﹤0.01%	265
2021 Q1	$358K	Hold	12,000	–	–	﹤0.01%	304
2020 Q4	$215K	Hold	12,000	–	–	﹤0.01%	225
2020 Q3	$229K	Sell	12,000 -500	-4%	-$8.83K	﹤0.01%	211
2020 Q2	$197K	Hold	12,500	–	–	﹤0.01%	150
2020 Q1	$171K	Sell	12,500 -40,087	-76%	-$511K	﹤0.01%	120
2019 Q4	$496K	Sell	52,587 -5,100	-9%	-$46.2K	0.01%	126
2019 Q3	$657K	Sell	57,687 -6,135	-10%	-$52.7K	0.01%	124
2019 Q2	$642K	Buy	+63,822	New	+$769K	0.01%	150

Other funds holding BCYC

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Pentwater Capital Management's BCYC Position: Q2 2022 in Review

Pentwater Capital Management sold out of Bicycle Therapeutics (BCYC) in Q2 2022, closing a stake of 14,000 shares — an estimated $614K sold.

Pentwater Capital Management first reported a position in BCYC in Q2 2019 and held it in 12 quarters. The position peaked at $2.4M in Q4 2021. 81 funds tracked by Wall St. Rank hold BCYC as of Q2 2022.

Pentwater Capital Management reported no remaining Bicycle Therapeutics position as of Q2 2022 after selling out during the quarter.
Pentwater Capital Management sold 14,000 Bicycle Therapeutics shares in Q2 2022, an estimated $614K.
Pentwater Capital Management first reported a position in Bicycle Therapeutics in Q2 2019 and held it in 12 quarters.
Pentwater Capital Management's Bicycle Therapeutics position peaked at $2.4M in Q4 2021.
81 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2022.

Based on Pentwater Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.